Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vytorin vs Simvastatin in High-Risk Acute Coronary Syndrome (IMPROVE-IT)
NCT00202878Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Oct 2005
- Primary completion
- Sep 2014
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ezetimibe in hypercholesterolemia and acute coronary syndrome (ACS) (2 arms), sponsored by Organon & Co. Primary endpoint: Major Adverse Cardiovascular Events at 9 years. Started Oct 2005; status: completed.
02
Drugs
ezetimibe
03
Conditions
hypercholesterolemiaacute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT00202878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00202878.